Cited by 1,763Computational Drug Discovery MethodsAnimal testing and alternativesStatistical Methods in Clinical Trials

The DOI matches its Crossref record; 105 of the 106 references it cites were found in a registry or an index.

Why 90% of clinical drug development fails and how to improve it?

Open access

Sun, Duxin, Gao, Wei, Hu, Hongxiang, Zhou, Simon·2022·Acta Pharmaceutica Sinica B

DOI 10.1016/j.apsb.2022.02.002PMC PMC9293739

Open this paper in CoChat — free account Open PDF

Abstract

Ninety percent of clinical drug development fails despite implementation of many successful strategies, which raised the question whether certain aspects in target validation and drug optimization are overlooked? Current drug optimization overly emphasizes potency/specificity using structure‒activity-relationship (SAR) but overlooks tissue exposure/selectivity in disease/normal tissues using structure‒tissue exposure/selectivity-relationship (STR), which may mislead the drug candidate selection and impact the balance of clinical dose/efficacy/toxicity. We propose structure‒tissue exposure/selectivity-activity relationship (STAR) to improve drug optimization, which classifies drug candidates based on drug's potency/selectivity, tissue exposure/selectivity, and required dose for balancing clinical efficacy/toxicity. Class I drugs have high specificity/potency and high tissue exposure/selectivity, which needs low dose to achieve superior clinical efficacy/safety with high success rate. Class II drugs have high specificity/potency and low tissue exposure/selectivity, which requires high dose to achieve clinical efficacy with high toxicity and needs to be cautiously evaluated. Class III drugs have relatively low (adequate) specificity/potency but high tissue exposure/selectivity, which requires low dose to achieve clinical efficacy with manageable toxicity but are often overlooked. Class IV drugs have low specificity/potency and low tissue exposure/selectivity, which achieves inadequate efficacy/safety, and should be terminated early. STAR may improve drug optimization and clinical studies for the success of clinical drug development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.apsb.2022.02.002

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hú, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,994
Lead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,455
A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Microfluidic organs-on-chips
Bhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305
Applications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D. A. E., & Janne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,092

Flagged first, then by citations

Show all 106 references

1 of the 106 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

Kerns, 2008, Chapter 2—advantages of good drug-like properties, 6
Kerns, 2008, Chapter 19 - pharmacokinetics, 228
Wei Gao, 2022, Structure‒tissue exposure/selectivity relationship (STR) may correlate with clinical efficacy/safety, Acta Pharm Sin B

Sorted by citations

Items 901–1,000 of 1,000

Engineering Cocrystals of Naringenin: New Solid Forms and Assessing Predictive Tools for Coformer Selection
Jadhav, S., Speranza, M. J., Nessler, A. J., Schnieders, M. J., & Stevens, L. L. (2025) · Crystal Growth & Design · doi:10.1021/acs.cgd.5c00222 · Cited by 2
Human intestinal enteroids: Nonclinical applications for predicting oral drug disposition, toxicity, and efficacy
O'Mahony, E. T., Arian, C. M., Aryeh, K. S., Wang, K., Thummel, K. E., & Kelly, E. J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108879 · Cited by 2
Sulforaphane treatment of HL-60 cells protects against clozapine toxicity and protein covalent binding: implications for clozapine-induced agranulocytosis
Rashid, M. H., Tran, N. H., Babu, D., Lockhart, S., Eldalal, O., Tran, P., Reiz, B., & Siraki, A. G. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111581 · Cited by 2
Sustainability by design for recombinant protein therapeutics
Mastrangeli, R., Audino, M. C., Fernandes, S. M., & Bierau, H. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104393 · Cited by 2
Chemical Properties-Based Deep Learning Models for Recommending Rational Daily Diet Combinations to Diabetics Through Large-Scale Virtual Screening of α-Glucosidase Dietary-Derived Inhibitors and Verified In Vitro
Liu, R., Gan, J.-W., Sun, M., Chen, H., Zou, W.-Y., Zou, S.-D., & Liu, S. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c03646 · Cited by 2
A thioridazine-derived molecule exhibits potential anti-inflammatory activity through IKK inhibition
Sarup, S., Atre, R., Obukhov, A. G., Tabrez, S. S. M., Yadav, P., Kshatri, A. S., Sk, M. H., Alamri, A. M., Khan, M. S., & Baig, M. S. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01786-y · Cited by 2
Twenty grams in two weeks: Material sparing tablet development of direct compression formulations for immediate release applications
Wood, C. C., Moreno, N. P. M., Drewke, J., Bramhall, J. A., Bell, S., & Locklin, J. (2025) · Powder Technology · doi:10.1016/j.powtec.2025.121299 · Cited by 2
In Silico Validation of AI-Assisted Drugs in Healthcare
Kapil, S., & Bagga, P. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4690-8_24 · Cited by 2
Galangin Nano‐Cocktail Balances Prodrug Activation and Antitumor Response for Enhanced Cancer Treatment
Wu, C., Wang, Y., Lin, Z., Yan, W., Chen, Q., Zhang, S., Sun, J., He, Z., & Luo, C. (2025) · Small · doi:10.1002/smll.202504254 · Cited by 2
Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects
Chadwick, J., Berry, C., Carpenter, M. A., Gulati, G., Heck, S. L., Hinterberg, M., Holman, R. R., Lee, M. M. Y., Omland, T., Paterson, C., et al. (2025) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70077 · Cited by 3
“Exploring flavonoids as potential therapeutics for diabetic neuropathy: ADMET predictions and molecular docking studies”
Gomes, A. K. C., Fiorot, R. G., Gomes, A. C. C., & Simas, N. K. (2025) · Natural Product Research · doi:10.1080/14786419.2025.2529558 · Cited by 2
Modulus‐Switchable Miniature Robots for Biomedical Applications: A Review
Wei, C., Wang, Y., & Yu, J. (2025) · Advanced Robotics Research · doi:10.1002/adrr.202500039 · Cited by 2
AGRL-DSE: Adaptive Graph Representation Learning on a Heterogeneous Graph for Drug Side Effect Prediction
Tan, H., Ji, X., Xu, C., Zhao, X., Hou, J., Liu, M., & Ren, Y. H. (2025) · ACS Omega · doi:10.1021/acsomega.5c04006 · Cited by 2
Controlling the Organization and Differentiation of Human Neural Stem Cells on Hilbert Microcapillary Scaffolds Fabricated via Two‐Photon Lithography
Harris, N., & Zou, M. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501355 · Cited by 3
Farnesol emulsion for elimination of Pseudomonas aeruginosa biofilm in a 3D airway model of cystic fibrosis
Tan, L., Sutton, K., Murphy, S. V., & Levi, N. (2025) · Biofilm · doi:10.1016/j.bioflm.2025.100317 · Cited by 2
Cathepsin C: a critical mediator between immune response and cardiovascular disease – therapeutic implications of enzyme inhibition
Aljabali, A. A. A., Obeid, M. A., Gammoh, O., Alshaer, W., Qnais, E. Y., Alqudah, A. M., Mishra, V. K., Mishra, Y., & El‐Tanani, M. (2025) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2025.2571722 · Cited by 2
Steroidal arylidene hybrids with phenolic moieties: Integrated in silico, DFT, and electrochemical evaluation for therapeutic targeting
Qaoud, M. T., Çapan, İ., Saydam, S., & Servi, S. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.144297 · Cited by 2
Exploring the Effectiveness of Three-Dimensional Molecular Representations in Caco-2 Permeability Prediction
Ng, P. B., & Lu, Y. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02019 · Cited by 2
Innovating pain research: bridging gaps and shaping the future
Rodríguez-Palma, E. J., Allen, H. N., Nelson, T. S., & Khanna, R. (2025) · Pain · doi:10.1097/j.pain.0000000000003661 · Cited by 2
Foundation Model for Medical Imaging: A Comprehensive Review
Jiao, L., Yang, J., Li, R., Liu, F., Liu, X., Chen, P., Guo, Y., Li, L., Shang, R., & Ma, W. (2025) · IEEE Transactions on Artificial Intelligence · doi:10.1109/tai.2025.3618796 · Cited by 4
Repurposing antimicrobials, disulfiram, and metformin for cancer therapy: Bridging mechanistic gaps through RNA sequencing
Hassan, S. N., & Ahmad, F. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178258 · Cited by 2
Enhanced drug recommendation model with graph contrastive based on singular value decomposition
Zeng, P., You, L., Zhang, B., Meng, Y., Tang, X., Zhang, Z., Cui, F., Jiang, J., & Xu, J. (2025) · Engineering Applications of Artificial Intelligence · doi:10.1016/j.engappai.2025.112674 · Cited by 2
Drug repurposing in oncology: a systematic review of anticancer effects of Lanatoside C at the molecular level
Olayode, O. O., Oladosu, T. J., Abioye, A. I., Oladeji, E. O., & Ogunoye, B. T. (2025) · BMC Cancer · doi:10.1186/s12885-025-15062-3 · Cited by 2
Intracellular Binding of Novel Fluorinated Compounds to Carbonic Anhydrase Isoforms Explored by In-Cell 19F NMR
Costantino, A., Barbieri, L., Giovannuzzi, S., Nocentini, A., Supuran, C. T., Raitelaitis, M., Nordlund, P., Banci, L., & Luchinat, E. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02227 · Cited by 2
Trialblazer: A chemistry-focused predictor of toxicity risks in late-stage drug development
Zhang, H., Welsch, M., Schueller, W., & Kirchmair, J. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118306 · Cited by 2
Benzohydrazide Analogs: Synthesis, Anticancer Screening, SAR, in Silico Molecular Docking, and ADMET Studies
Solanki, V. H., Patel, U. P., Baloch, M. M., & Naliapara, Y. T. (2025) · ChemistrySelect · doi:10.1002/slct.202503196 · Cited by 2
A Critical Reassessment of Tumor Metastasis Simulation in Murine Models: Insights Into Methodological Advances and Biological Relevance
Li, X., Ren, W., Liu, L., Liu, C., & Chen, X. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202500277 · Cited by 2
Wearable nanopatch platforms for real-time miRNA sensing and editing: a vision for next-generation cancer management
Ameya, K. P., Ross, K., & Sekar, D. (2025) · Medical Oncology · doi:10.1007/s12032-025-03091-8 · Cited by 2
Investigating Adhesion Molecules in Stem Cell – Immune Cell Interactions Using Organoids
Rotondi, L., Li, F.-C., Magalhães, M. A. O., & Kishen, A. (2025) · Journal of Endodontics · doi:10.1016/j.joen.2025.11.007 · Cited by 2
Embedded Coaxial Bioprinting of Vascularized Tissue Models for Drug Evaluation
Sun, J., Gong, Y., He, Y., Cui, J., Chen, H., Kang, N., Wu, Y., Hui, J., Chen, H., Zhou, R., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202520097 · Cited by 2
3D bioprinting innovations: a new frontier in breast cancer research
Seifi, Z., Khazaei, M., Dayani, M., Zamani, S., Abdalla, S. B., & Rezakhani, L. (2025) · Medical Oncology · doi:10.1007/s12032-025-03069-6 · Cited by 3
Advancing transcriptomics-based mechanistic assessment of nephrotoxicity in vitro using the human RPTEC/TERT1 TXG-MAPr gene co-expression network
van Kessel, H. W., Kunnen, S. J., Callegaro, G., & van de Water, B. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf159 · Cited by 2
Lymph node paracortex-inspired on-a-chip recapitulating immunosenescence: a cancer vaccine immunogenicity and antitumoral efficacy screening platform
Maity, S., Najafabadi, A. H., Kawakita, S., Khorsandi, D., Yilgor, C., Jewell, C., Mohaghegh, N., Dokmeci, M. R., Khademhosseini, A., & Jucaud, V. (2025) · Lab on a Chip · doi:10.1039/d5lc00533g · Cited by 5
Advancing anticancer chelation therapy: Insights from enhancing cytotoxic potency, targeted cellular delivery, metal-based immunomodulation, and combinatorial strategies
Acosta, C., Claudio-Ares, O., Ullah, I., Cruz, L. C., Ducey, A. C., Vidal, A., Escalante-Castaneda, A., Maldonado-Santos, A. R., Liu, B., Villanueva, C. N., et al. (2025) · Inorganica Chimica Acta · doi:10.1016/j.ica.2025.123004 · Cited by 2
Smart nanocarriers in triple-negative breast cancer: recent advances in targeting and translational application
Mishra, A., Gole, V. L., & Ojha, S. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-02022-4 · Cited by 3
Molecular life sciences in the era of the Fourth Industrial Revolution: sequencing, multi-omics and artificial intelligence
Keenan, L., Younger, R. M., Race, P. R., & Bawn, M. (2025) · Emerging Topics in Life Sciences · doi:10.1042/etls20253019 · Cited by 2
Established and emerging new approach methodologies in neuroscience
Imberechts, D., Ny, A., & Copmans, D. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1696937 · Cited by 4
A Comprehensive Analysis of Natural Bioactive Molecules for the Treatment and Control of Glioblastoma Multiforme (GBM) Targeting Underlying Molecular Mechanism
Parvez, A., Rahman, M. A., Shimki, A. I., Biswas, P., Hasan, M. H., Imtiaz, M., Sultana, A., Islam, S., Faraque, A., Amin, M. F., et al. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202501413 · Cited by 4
Chitosan conjugated cyclodextrin nanocomposite loaded with antibiotic-adjuvant combinations remediates multi-drug resistant Staphylococcus aureus infection in CD-1 mice model of bovine mastitis
Majumder, S., Millette, G., Sackey, T., Malouin, F., & George, S. (2025) · Nanoscale · doi:10.1039/d5nr03837e · Cited by 2
Deep learning for small-molecule drug discovery: From molecular design to clinical translation
Oliveira, R. I., Pereira, T., Abbasi, M., Salvador, J. A. R., & Arrais, J. P. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101533 · Cited by 4
Generative artificial intelligence in pharmaceutical drug development: A systematic review of time and cost efficiency across discovery, preclinical, and clinical phases
Riemer, A., & Freund, V. (2026) · Intelligent Pharmacy · doi:10.1016/j.ipha.2025.12.006 · Cited by 3
Healing of ischemic injury in the retina
Becker, S., L'Ecuyer, Z., Allen, J., Saeid, S., Sturgis, L., Adderley, A., Koskelainen, A., & Vinberg, F. (2026) · Science Advances · doi:10.1126/sciadv.adx7204 · Cited by 2
Predictive value of the hERG assay for anticipating the arrhythmogenic potential of new drugs
Matos, C. A., Ali, N., Augusto, A., Algarvio, R. C., Figueirinha, J., & Conceição, J. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104615 · Cited by 2
The predictive edge: modeling and simulation in drug product development
Konagurthu, S., Ranathunga, D. T. S., Buchanan, S., Mehta, N. M., & Reynolds, T. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115784 · Cited by 2
Integration of artificial intelligence and machine learning technologies in antiviral drug discovery: strategies and challenges
Kamboj, S., & Kumar, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34059-8.00002-6 · Cited by 2
De novo protein design: a transformative frontier in clinical protein applications
Gao, J., Zheng, Z., Yu, X., Luo, Y., Yu, Y., & Zhang, C. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07784-0 · Cited by 3
The gene expression landscape of disease genes
García‐González, J., Cote, A. C., Garcia-Gonzalez, S., Liou, L., & O’Reilly, P. F. (2026) · Genome biology · doi:10.1186/s13059-026-03958-7 · Cited by 6
Emerging Trends in Phytochemical Nanomedicines for Lung Inflammation and Fibrosis Management
Shetty, D. M., Balnadupete, A., Bhandary, Y. P., Uthaman, S., & Johnson, R. P. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202504927 · Cited by 2
Unraveling Network Pharmacology‐Based Therapeutics of Anthranilate Sulfonamides via Sirtuins/ FOXO3a Cascade in Alzheimer's Disease
Ruankham, W., Prachayasittikul, V., Pingaew, R., Jeungprasopsuk, W., Tantimongcolwat, T., Prachayasittikul, V., Prachayasittikul, S., & Phopin, K. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70377 · Cited by 2
The application of experimental models for the drug discovery for digestive tumors
Zheng, L., Shuai, W., Liu, Y., Deng, Y., Bao, J., Hu, X., & Wang, G. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02558-6 · Cited by 2
Effect of modulation of alimentary and formulation pH on the pharmacokinetics of BCS-Class I, II, III, and IV compounds in rats following cassette dosing
Kumar, S., Tattala, L. P., AkkiReddy, R., Singh, S., Tiwari, S. K., Srivastava, P., Gupta, S., & Nair, A. B. (2026) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2026.2635383 · Cited by 4
Organoid Models of the Oral Mucosa for Precision Medicine
Atwa, A., Wadan, A. S., Hallool, S. I., Shati, A. A., Elbehairi, S. E. I., Alfaifi, M. Y., & Hussein, A. M. (2026) · Tissue Engineering Part B Reviews · doi:10.1177/19373368261420588 · Cited by 3
Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades
Bialer, M., & Perucca, E. (2026) · Drugs · doi:10.1007/s40265-026-02297-y · Cited by 3
Repurposing DrugBank compounds as NAD-dependent deacetylase sirtuin 2 inhibitors via QSAR modelling with gradient boosting algorithms and all-atom molecular simulations
Boulaamane, Y., Saih, A., Guendouzi, A., & Maurady, A. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11504-7 · Cited by 2
Drug repurposing in oncology: Bridging computational discovery to clinical application
Baskar, S., & Prasad, N. R. (2026) · International Journal of Cancer · doi:10.1002/ijc.70429 · Cited by 2
Drug-likeness prioritised selection identifies anti- Escherichia coli candidates confirmed by molecular docking, dynamics simulations, and antibacterial assays
Yu, B., Zhu, H., Xu, L., Zhao, X., & Shi, W. F. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2640719 · Cited by 2
Translating Pharmacology from Animal Models to Organoids: Advancing Predictive Human Biology in Drug Discovery
Patel, G., & Amin, H. (2026) · Stem Cell Reviews and Reports · doi:10.1007/s12015-026-11096-7 · Cited by 2
Human-Centric Modeling in Metastatic Breast Cancer: Organoids, Organ-on-Chip Systems, and New Approach Methodologies in the Post-FDA Modernization Act 2.0 Era
Alatawi, H., Nair, H. H., Raza, A., Vélez, E. D., Sharma, A. K., & Narayan, S. (2026) · Cancers · doi:10.3390/cancers18071166 · Cited by 2
The history of β-aminoisobutyric acid: from a waste metabolite to a druggable compound for metabolic disease. A narrative review
Begriche, K., Massart, J., & Fromenty, B. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178879 · Cited by 2
Modernizing drug development and ensuring global equity in the organoid revolution
Dzakah, E. E., Ni, C., Feng, X., Hu, W., Zhao, B. T., Tang, S., & Pang, C. (2026) · Communications Biology · doi:10.1038/s42003-026-10076-4 · Cited by 2
CS-DTA: a language model-driven framework for robust drug-target affinity prediction under strict cold-start scenarios
Jiang, Z., Dai, H., Chen, Y., Qiao, B., & Sun, S. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1834317 · Cited by 2
Bridging diagnosis and therapeutics: The role of AI in cancer detection and drug development
Barua, S., Balaji, B., & Balaji, S. (2026) · Health Sciences Review · doi:10.1016/j.hsr.2026.100270 · Cited by 2
Microfluidics meets organoids: Kidney and bladder-on-Chip models for preclinical drug delivery assessment
Ma, C., Koh, D., Nishimura, T., Takata, Y., Kameda, Y., Negoro, R., Ishiguro, N., Shibuta, M., Namatame, I., Tetsuka, K., et al. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115887 · Cited by 2
Socioenvironmental determinants of polypharmacy in mental health disorders: a systematic review
Tegegne, G. T., Tabatabaei‐Jafari, H., Niyonsenga, T., Ghiasvand, S., Bagheri, Y., & Bagheri, N. (2026) · BMC Public Health · doi:10.1186/s12889-026-27658-w · Cited by 2
End-to-end automation of organ-on-a-chip culture and drug testing: Enhancing scalability and expandability
Shibuta, M., Tetsuka, K., Kawabe, T., Namatame, I., Asano, H., Heijmans, J., Wevers, N. R., & Sasaki-Iwaoka, H. (2026) · SLAS TECHNOLOGY · doi:10.1016/j.slast.2026.100434 · Cited by 2
Electrospun Nanofibers for Small Molecule Sustained Delivery Targeting Articular Cartilage Regeneration: A Review
Barbosa, F., Miguel, F., Domingues, M. F., & Silva, J. C. (2026) · Fibers · doi:10.3390/fib14050056 · Cited by 2
ToxiGuard: an AOP-guided mechanistically interpretable framework for multi-organ toxicity prediction
Zhao, C., Wang, J., Bo, X., & He, S. (2026) · Archives of Toxicology · doi:10.1007/s00204-026-04436-6 · Cited by 2
Insights From Spatiality: Accelerating Pharmaceutical Research Using Mass Spectrometry Imaging
Zou, Y., Yan, Z., Tang, W., & Li, B. (2026) · Medicinal Research Reviews · doi:10.1002/med.70061 · Cited by 2
Engineering Organoid Platforms for Pathogenesis Research
Gao, X., Han, X., Bai, J., Tian, W., Zhou, J., Ding, L., & Gao, X. (2026) · Research · doi:10.34133/research.1346 · Cited by 2
Applying Deep-Learning-Driven De Novo Design to Hit Identification: A Case Study on A 2A Adenosine Receptor Antagonists
Persico, M., Micoli, A., Salmaso, V., Cianciulli, A., Moro, S., Spalluto, G., Buccioni, M., Marucci, G., Volpini, R., Pozzan, A., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00231 · Cited by 2
Privileged nitrogen heterocycles in anticancer drug discovery: recent advances on imidazole, indole, and pyrimidine scaffolds
Govindarajan, M., Maji, L., Mannathan, S., Kathiravan, M. K., Chowdhury, A., Jois, S. D. S., & Baskar, B. (2026) · RSC Advances · doi:10.1039/d6ra02591a · Cited by 2
Integrated Evidence Generation Planning: Why Medical Affairs is a Critical Partner
Fujii, R., Nouri, M., Khan, M., Fleisinger, L., Pugh, J., Male, G., & Panayi, A. (2026) · Pharmaceutical Medicine · doi:10.1007/s40290-026-00620-2 · Cited by 2
Closing the Translational Gap: Closed‐Loop AI Discovery Frameworks for Experimental Validation and Clinical Implementation in Cancer Therapeutics
Varol, T. Ö., & Varol, M. (2026) · Cancer Medicine · doi:10.1002/cam4.72193 · Cited by 2
Antiviral Drug Discovery in Emerging Economics
Navabhatra, A., & Yangchaiya, C. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-9276-8.ch004 · Cited by 2
Evaluation of the potential of N-acetylcysteine in Alzheimer's disease
Fernandes, I. D. C., Leite, D. R. B., de Oliveira, V. D. G. S. B., Dias, J. D. F. G., Montrucchio, D. P., de Oliveira, V. B., Dalarmi, L., Miguel, M. D., & Miguel, O. G. (2023) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e12117.2023 · Cited by 2
Analysis of intracellular tyrosine phosphorylation in circulating neutrophils as a rapid assay for the in vivo effect of oral tyrosine kinase inhibitors
Futosi, K., Bajza, B., Deli, D., Erdélyi, A., Tusnády, S., & Mócsai, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1056154 · Cited by 2
Learning to think critically
Barnes, B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817134-9.00013-1 · Cited by 2
Technologies and Innovations for Smart Health Care System in Society 5.0
Yadav, N., Bala, S., Thakur, L., Yadav, N., & Yadav, D. (2023) · Springer eBooks · doi:10.1007/978-981-99-6472-7_10 · Cited by 2
In Search of Novel SGLT2 Inhibitors by High-throughput Virtual Screening
Debnath, A., Sharma, S., Mazumder, R., Mazumder, A., Singh, R. K., Kumar, A., Dua, A., Singhal, P., Kumar, A., & Singh, G. (2023) · Current Drug Discovery Technologies · doi:10.2174/0115701638267615231123160650 · Cited by 2
Psychotropics: A scientific, regulatory, and public view on the medicinal uses of cannabinoids and psilocybin
Turek, I. (2023) · Medical Writing · doi:10.56012/tsen2260 · Cited by 2
Computational chemistry of natural product analogues
Majhi, S., & Manickam, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15269-6.00009-2 · Cited by 2
stanscofi and benchscofi: a new standard for drug repurposing by collaborative filtering
Réda, C., Vie, J.-J., & Olaf Wolkenhauer, A. (2024) · The Journal of Open Source Software · doi:10.21105/joss.05973 · Cited by 2
In-vitro gadolinium retro-microdialysis in agarose gel—a human brain phantom study
Zimphango, C., Mada, M., Sawiak, S. J., Giorgi-Coll, S., Carpenter, T. A., Hutchinson, P. J., Carpenter, K. L. H., & Stovell, M. G. (2024) · Frontiers in Radiology · doi:10.3389/fradi.2024.1085834 · Cited by 2
Yeast-Based Screening of Anti-Viral Molecules
Srivastava, V., Kumar, R., & Ahmad, A. (2024) · Microorganisms · doi:10.3390/microorganisms12030578 · Cited by 2
Artificial Intelligence Is a Game Changer in Drug Discovery R&D
Ermak, T. (2024) · Management for professionals · doi:10.1007/978-3-031-47768-3_2 · Cited by 2
Development of a long term, ex vivo, patient-derived explant model of endometrial cancer
van der Woude, H., Phan, K., Kenwright, D., Goossens, L., Hally, K. E., Currie, M. J., Kokkinos, J., Sharbeen, G., Phillips, P. A., & Henry, C. E. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301413 · Cited by 2
Molecular Docking and Computational In Silico Investigations of Metal-Based Drug Agents
Arjmand, F., Tabassum, S., & Khan, H. Y. (2024) · Springer eBooks · doi:10.1007/978-981-97-0146-9_6 · Cited by 4
Design and synthesis of novel factor XIa Inhibitors with bicyclic isoquinoline and naphthalene fragments
Zhang, Y., Dai, L., Tan, Y., Yu, Y., Xing, J., Yang, F., Ren, B., Xu, Y., & Li, Q. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03245-9 · Cited by 2
Deep learning methods for drug repurposing through heterogeneous data
Papikinos, T., Krokidis, M. G., Vrahatis, A. G., Vlachakis, D., Vlamos, P., & Exarchos, T. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19073-5.00005-7 · Cited by 2
Cross‐species signaling pathways analysis inspire animal model selections for drug screening and target prediction in vascular aging diseases
Sun, F., Chen, X., Zhang, S., Jiang, H., Chen, T., Xing, T., Li, X., Sultan, R., Wang, Z., & Jia, J. (2024) · Evolutionary Applications · doi:10.1111/eva.13708 · Cited by 2
In vitro neuroprotective effects and in silico evaluation of the pharmacological potential of two phenolic acids and a derivative originated from the edible red macroalga (Bangia fuscopurpurea)
Huang, S., Hsieh, C., & Feng, C. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106322 · Cited by 2
Harnessing Artificial Intelligence in Drug Discovery: Revolutionizing Chemical and Biochemical Sciences
Dash, B. (2024) · doi:10.48047/afjbs.6.3.2024.496-507 · Cited by 2
Applying quantitative and systems pharmacology to drug development and beyond: An introduction to clinical pharmacologists
Ramasubbu, M. K., Paleja, B. S., Srinivasann, A., Maiti, R., & Kumar, R. (2024) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_644_23 · Cited by 2
Computational Approaches for Structure-Assisted Drug Discovery and Repurposing
Pandey, A. K., & Verma, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-7123-3_9 · Cited by 3
Bioprospection for antiviral compounds from selected medicinal plants against RNA polymerase of rotavirus A using molecular modelling and density functional theory
Lanrewaju, A. A., Folami, A. M., Sabiu, S., & Swalaha, F. M. (2024) · Chemical Physics Impact · doi:10.1016/j.chphi.2024.100745 · Cited by 2
RUTHENIUM ORGANOMETALLIC COMPOUNDS IN CANCER TREATMENT
Sikkander, A. R. M. (2024) · Biomedical Engineering Applications Basis and Communications · doi:10.4015/s1016237224300037 · Cited by 10
ВИКОРИСТАННЯ МЕТОДІВ ДОСЛІДЖЕНЬ IN SILICO ДЛЯ ПРОГНОЗУВАННЯ ФАРМАКОКІНЕТИЧНИХ ВЛАСТИВОСТЕЙ ТА ПОШУКУ БІОЛОГІЧНО АКТИВНИХ РЕЧОВИН
Zahrychuk, O. H., Matyashchuk, U. O., Korjovska, V. V., Мілян, І. І., Poliovyi, D. O., Zahrychuk, H. Y., & Demyd, A. Y. (2024) · Фармацевтичний часопис · doi:10.11603/2312-0967.2024.3.14868 · Cited by 2
Epoxy-a-lapachone in nanosystem: a prototype drug for leishmaniasis assessed in the binomial BALB/c - Leishmania (Leishmania) amazonensis
Peixoto, J. F., Gonçalves-Oliveira, L. F., Dias-Lopes, G., Souza‐Silva, F., & Alves, C. R. (2024) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760240115 · Cited by 2
In silico studies for improving target selectivity of anti-malarial dual falcipain inhibitors vis-à-vis human cathepsins
Patra, J., Arora, S., Debnath, U., & Mahindroo, N. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2427372 · Cited by 2
Leveraging Corporate Assets and Talent to Attract Investors in Japan: A Country with an Innovation System Centered on Large Companies
Okuyama, R. (2024) · Journal of risk and financial management · doi:10.3390/jrfm17120539 · Cited by 2

Authors: Sun, D., Gao, W., Hu, H., & Zhou, S.
Affiliations: University of Michigan (US)
Bristol-Myers Squibb (United States) (US)
Corresponding author: Sun, Duxin
ORCID: Sun, Duxin
Gao, Wei
Hu, Hongxiang
Zhou, Simon
Venue: Acta Pharmaceutica Sinica B
Publisher: Elsevier BV
Published: 2022-07
Volume: 12
Issue: 7
Pages: 3049-3062
ISSN: 2211-3835 (ISSN-L)
DOI: 10.1016/j.apsb.2022.02.002
PMC: PMC9293739
OpenAlex: W4211238337
Cited by: 1,763
References: 106
Citations by year: 2026: 482 · 2025: 550 · 2024: 456 · 2023: 230 · 2022: 45
FWCI: 27.77
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Acta Pharmaceutica Sinica B (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords: medication optimization, tissue selectivity, structure-activity relationship, target validation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Why 90% of clinical drug development fails and how to improve it?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks